TRIAL DETAIL
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Recruiting |
|||
Phase: |
3 |
Start Date 09/12/2020 |
Age of Trial (yrs) 3.6 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor + VEGF inhibitor |
|||
Strategy: |
Block KIT/PDGFRA |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
SHR-1020-â…¢-303 |
|||
Sponsor: |
Jiangsu HengRui Medicine Co., Ltd. |
|||
Patient Contact: |
Quanren Wang, MD
(+86) 021-50118402
wangquanren@hrglobe.cn |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
Randomized |
|||
IV or Oral: |
Oral |
|||
Trial Notes: |
A Phase III, Open Label, Randomised，Controlled, Multi-centre Study to Assess the Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Beijing |
100036 |
China |